LSD1 regulates pluripotency of embryonic stem/carcinoma cells through histone deacetylase 1-mediated deacetylation of histone H4 at lysine 16

Molecular and Cellular Biology

Volumn 34, Issue 2, 2014, Pages 158-179

  Yin, Feng ^a   Lan, Rongfeng ^a   Zhang, Xiaoming ^a   Zhu, Linyu ^a   Chen, Fangfang ^a   Xu, Zhengshuang ^a   Liu, Yuqing ^b   Ye, Tao ^b   Sun, Hong ^c   Lu, Fei ^a   Zhang, Hui ^a,c  

^a PEKING UNIVERSITY   (China)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^c UNIVERSITY OF NEVADA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; FLAVINE ADENINE NUCLEOTIDE; HEPATOCYTE NUCLEAR FACTOR 3BETA; HISTONE DEACETYLASE 1; HISTONE H4; LYSINE; LYSINE SPECIFIC DEMETHYLASE 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DEACETYLATION; EMBRYONAL CARCINOMA STEM CELL; ENZYME ACTIVITY; ENZYME INACTIVATION; FEMALE; GROWTH INHIBITION; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; WESTERN BLOTTING;

EID: 84891401740     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00631-13     Document Type: Article

References (49)

1. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA. 2004. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119:941-953. http://dx.doi.org/10.1016/j.cell.2004.12.012.
2. Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH, Gunther T, Buettner R, Schule R. 2005. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437:436-439. http://dx.doi.org/10.1038/nature04020.
3. Shi YJ, Matson C, Lan F, Iwase S, Baba T, Shi Y. 2005. Regulation of LSD1 histone demethylase activity by its associated factors. Mol. Cell 19: 857-864. http://dx.doi.org/10.1016/j.molcel.2005.08.027.
4. Lee MG, Wynder C, Cooch N, Shiekhattar R. 2005. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 437: 432-435. http://dx.doi.org/10.1038/nature04021.
5. Shi Y, Sawada J, Sui G, Affar el B, Whetstine JR, Lan F, Ogawa H, Luke MP, Nakatani Y. 2003. Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature 422:735-738. http://dx.doi.org/10.1038/nature01550.
6. Wang Y, Zhang H, Chen Y, Sun Y, Yang F, Yu W, Liang J, Sun L, Yang X, Shi L, Li R, Li Y, Zhang Y, Li Q, Yi X, Shang Y. 2009. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138:660-672. http://dx.doi.org/10.1016/j.cell.2009.05.050.
7. Wang J, Hevi S, Kurash JK, Lei H, Gay F, Bajko J, Su H, Sun W, Chang H, Xu G, Gaudet F, Li E, Chen T. 2009. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat. Genet. 41:125-129. http://dx.doi.org/10.1038/ng.268.
8. Adamo A, Sese B, Boue S, Castano J, Paramonov I, Barrero MJ, Izpisua Belmonte JC. 2011. LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells. Nat. Cell Biol. 13:652-659. http://dx.doi.org/10.1038/ncb2246.
9. Whyte WA, Bilodeau S, Orlando DA, Hoke HA, Frampton GM, Foster CT, Cowley SM, Young RA. 2012. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Nature 482:221-225. http://dx.doi.org/10.1038/nature10805.
10. Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, Ciceri F, Blaser JG, Greystoke BF, Jordan AM, Miller CJ, Ogilvie DJ, Somervaille TC. 2012. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 21:473-487. http://dx.doi.org/10.1016/j.ccr.2012.03.014.
11. Sun G, Alzayady K, Stewart R, Ye P, Yang S, Li W, Shi Y. 2010. Histone demethylase LSD1 regulates neural stem cell proliferation. Mol. Cell. Biol. 30:1997-2005. http://dx.doi.org/10.1128/MCB.01116-09.
12. Lim S, Janzer A, Becker A, Zimmer A, Schule R, Buettner R, Kirfel J. 2010. Lysine-specific demethylase 1 (LSD1) is highly expressed in ERnegative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 31:512-520. http://dx.doi.org/10.1093/carcin/bgp324.
13. Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, Ora I, Pajtler K, Klein-Hitpass L, Kuhfittig-Kulle S, Metzger E, Schule R, Eggert A, Buettner R, Kirfel J. 2009. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res. 69:2065-2071. http://dx.doi.org/10.1158/0008-5472.CAN-08-1735.
14. Bennani-Baiti IM, Machado I, Llombart-Bosch A, Kovar H. 2012. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum. Pathol. 43:1300-1307. http://dx.doi.org/10.1016/j.humpath.2011.10.010.
15. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, Solleder G, Bastian PJ, Ellinger J, Metzger E, Schule R, Buettner R. 2006. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 66:11341-11347. http://dx.doi.org/10.1158/0008-5472.CAN-06-1570.
16. Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, Field HI, Neal DE, Yamaue H, Ponder BA, Nakamura Y, Hamamoto R. 2011. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 128:574-586. http://dx.doi.org/10.1002/ijc.25349.
17. Wang J, Lu F, Ren Q, Sun H, Xu Z, Lan R, Liu Y, Ward D, Quan J, Ye T, Zhang H. 2011. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res. 71: 7238-7249. http://dx.doi.org/10.1158/0008-5472.CAN-11-0896.
18. Dovey OM, Foster CT, Cowley SM. 2010. Histone deacetylase 1 (HDAC1), but not HDAC2, controls embryonic stem cell differentiation. Proc. Natl. Acad. Sci. U. S. A. 107:8242-8247. http://dx.doi.org/10.1073/pnas.1000478107.
19. Rajendran P, Ho E, Williams DE, Dashwood RH. 2011. Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells. Clin. Epigenetics 3:4. http://dx.doi.org/10.1186/1868-7083-3-4.
20. Downs JA. 2008. Histone H3 K56 acetylation, chromatin assembly, and the DNA damage checkpoint. DNA Repair (Amst.) 7:2020-2024. http://dx.doi.org/10.1016/j.dnarep.2008.08.016.
21. Li Q, Zhou H, Wurtele H, Davies B, Horazdovsky B, Verreault A, Zhang Z. 2008. Acetylation of histone H3 lysine 56 regulates replicationcoupled nucleosome assembly. Cell 134:244-255. http://dx.doi.org/10.1016/j.cell.2008.06.018.
22. Maas NL, Miller KM, DeFazio LG, Toczyski DP. 2006. Cell cycle and checkpoint regulation of histone H3 K56 acetylation by Hst3 and Hst4. Mol. Cell 23:109-119. http://dx.doi.org/10.1016/j.molcel.2006.06.006.
23. Xie W, Song C, Young NL, Sperling AS, Xu F, Sridharan R, Conway AE, Garcia BA, Plath K, Clark AT, Grunstein M. 2009. Histone H3 lysine 56 acetylation is linked to the core transcriptional network in human embryonic stem cells. Mol. Cell 33:417-427. http://dx.doi.org/10.1016/j.molcel.2009.02.004.
24. Yuan J, Pu M, Zhang Z, Lou Z. 2009. Histone H3-K56 acetylation is important for genomic stability in mammals. Cell Cycle 8:1747-1753. http://dx.doi.org/10.4161/cc.8.11.8620.
25. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C. 2002. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 21:2672-2681. http://dx.doi.org/10.1093/emboj/21.11.2672.
26. Glozak MA, Seto E. 2007. Histone deacetylases and cancer. Oncogene 26:5420-5432. http://dx.doi.org/10.1038/sj.onc.1210610.
27. Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Liu J, Lu AH, Zhou NZ, Robert MF, Gillespie J, Wang JJ, Ste-Croix H, Rahil J, Lefebvre S, Moradei O, Delorme D, Macleod AR, Besterman JM, Li Z. 2008. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer Ther. 7:759-768. http://dx.doi.org/10.1158/1535-7163.MCT-07-2026.
28. Hayashi A, Horiuchi A, Kikuchi N, Hayashi T, Fuseya C, Suzuki A, Konishi I, Shiozawa T. 2010. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. Int. J. Cancer 127:1332-1346. http://dx.doi.org/10.1002/ijc.25151.
29. Higashijima J, Kurita N, Miyatani T, Yoshikawa K, Morimoto S, Nishioka M, Iwata T, Shimada M. 2011. Expression of histone deacetylase 1 and metastasis-associated protein 1 as prognostic factors in colon cancer. Oncol. Rep. 26:343-348. http://dx.doi.org/10.3892/or.2011.1312.
30. Gao DJ, Xu M, Zhang YQ, Du YQ, Gao J, Gong YF, Man XH, Wu HY, Jin J, Xu GM, Li ZS. 2010. Upregulated histone deacetylase 1 expression in pancreatic ductal adenocarcinoma and specific siRNA inhibits the growth of cancer cells. Pancreas 39:994-1001. http://dx.doi.org/10.1097/MPA.0b013e3181db0086.
31. Minamiya Y, Ono T, Saito H, Takahashi N, Ito M, Mitsui M, Motoyama S, Ogawa J. 2011. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer 74:300-304. http://dx.doi.org/10.1016/j.lungcan.2011.02.019.
32. Al-Janadi A, Chandana SR, Conley BA. 2008. Histone deacetylation: an attractive target for cancer therapy? Drugs R D 9:369-383. http://dx.doi.org/10.2165/0126839-200809060-00003.
33. Witt O, Deubzer HE, Milde T, Oehme I. 2009. HDAC family: what are the cancer relevant targets? Cancer Lett. 277:8-21. http://dx.doi.org/10.1016/j.canlet.2008.08.016.
34. Rea S, Xouri G, Akhtar A. 2007. Males absent on the first (MOF): from flies to humans. Oncogene 26:5385-5394. http://dx.doi.org/10.1038/sj.onc.1210607.
35. Conrad T, Cavalli FM, Holz H, Hallacli E, Kind J, Ilik I, Vaquerizas JM, Luscombe NM, Akhtar A. 2012. The MOF chromobarrel domain controls genome-wide H4K16 acetylation and spreading of the MSL complex. Dev. Cell 22:610-624. http://dx.doi.org/10.1016/j.devcel.2011.12.016.
36. Gelbart ME, Larschan E, Peng S, Park PJ, Kuroda MI. 2009. Drosophila MSL complex globally acetylates H4K16 on the male X chromosome for dosage compensation. Nat. Struct. Mol. Biol. 16:825-832. http://dx.doi.org/10.1038/nsmb.1644.
37. Wells MB, Snyder MJ, Custer LM, Csankovszki G. 2012. Caenorhabditis elegans dosage compensation regulates histone H4 chromatin state on X chromosomes. Mol. Cell. Biol. 32:1710-1719. http://dx.doi.org/10.1128/MCB.06546-11.
38. Li X, Li L, Pandey R, Byun JS, Gardner K, Qin Z, Dou Y. 2012. The histone acetyltransferase MOF is a key regulator of the embryonic stem cell core transcriptional network. Cell Stem Cell 11:163-178. http://dx.doi.org/10.1016/j.stem.2012.04.023.
39. Pushpavalli SN, Sarkar A, Ramaiah MJ, Chowdhury DR, Bhadra U, Pal-Bhadra M. 2013. Drosophila MOF controls Checkpoint protein2 and regulates genomic stability during early embryogenesis. BMC Mol. Biol. 14:1. http://dx.doi.org/10.1186/1471-2199-14-1.
40. Gupta A, Guerin-Peyrou TG, Sharma GG, Park C, Agarwal M, Ganju RK, Pandita S, Choi K, Sukumar S, Pandita RK, Ludwig T, Pandita TK. 2008. The mammalian ortholog of Drosophila MOF that acetylates histone H4 lysine 16 is essential for embryogenesis and oncogenesis. Mol. Cell. Biol. 28:397-409. http://dx.doi.org/10.1128/MCB.01045-07.
41. Pfister S, Rea S, Taipale M, Mendrzyk F, Straub B, Ittrich C, Thuerigen O, Sinn HP, Akhtar A, Lichter P. 2008. The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int. J. Cancer 122:1207-1213. http://dx.doi.org/10.1002/ijc.23283.
42. Wang Y, Zhang R, Wu D, Lu Z, Sun W, Cai Y, Wang C, Jin J. 2013. Epigenetic change in kidney tumor: downregulation of histone acetyltransferase MYST1 in human renal cell carcinoma. J. Exp. Clin. Cancer Res. 32:8. http://dx.doi.org/10.1186/1756-9966-32-8.
43. Jin J, Arias EE, Chen J, Harper JW, Walter JC. 2006. A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol. Cell 23:709-721. http://dx.doi.org/10.1016/j.molcel.2006.08.010.
44. Lan R, Lin G, Yin F, Xu J, Zhang X, Wang J, Wang Y, Gong J, Ding YH, Yang Z, Lu F, Zhang H. 2012. Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001. Lab. Invest. 92:1503-1514. http://dx.doi.org/10.1038/labinvest.2012.114.
45. Shi Y. 2007. Histone lysine demethylases: emerging roles in development, physiology and disease. Nat. Rev. Genet. 8:829-833. http://dx.doi.org/10.1038/nrg2218.
46. Jurkin J, Zupkovitz G, Lagger S, Grausenburger R, Hagelkruys A, Kenner L, Seiser C. 2011. Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis. Cell Cycle 10:406-412. http://dx.doi.org/10.4161/cc.10.3.14712.
47. Haberland M, Johnson A, Mokalled MH, Montgomery RL, Olson EN. 2009. Genetic dissection of histone deacetylase requirement in tumor cells. Proc. Natl. Acad. Sci. U. S. A. 106:7751-7755. http://dx.doi.org/10.1073/pnas.0903139106.
48. Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, Reinberg D. 2004. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol. Cell 16:93-105. http://dx.doi.org/10.1016/j.molcel.2004.08.031.
49. Dou Y, Milne TA, Tackett AJ, Smith ER, Fukuda A, Wysocka J, Allis CD, Chait BT, Hess JL, Roeder RG. 2005. Physical association and coordinate function of theH3K4 methyltransferase MLL1 and theH4K16 acetyltransferase MOF. Cell 121:873-885. http://dx.doi.org/10.1016/j.cell.2005.04.031.